Emerging Pharma Markets: Adapt, Diversify, and Persist

Emerging global markets are a hot topic in pharmaceutical circles these days, but until recently, most Westerners viewed them as a homogenous cluster. Few executives at corporate headquarters drew distinctions among the various countries, let alone the domestic and international players in those markets. As big pharma bumps up against growth constraints in its traditional markets, however, interest in the "rest of the world" is perking up. The largest pharmaceutical companies are all looking at the same promising half dozen or so emerging countries, but they are taking radically different approaches to tackling them and are moving at different paces.

By Wendy Diller

Emerging markets are a hot topic in pharmaceutical circles these days, but until recently, most Westerners viewed them as a...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

This is a test

 

Just running through to check Confluence instructions make sense

H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By 

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 
• By 

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.